Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

Barclays analyst Glen Santangelo has initiated coverage on Ligand Pharmaceuticals (NASDAQ: LGND) with an Overweight rating. The firm has set a price target of $345 for the company's stock.